Novartis to acquire Avidity Biosciences in $12B deal

Novartis will acquire Avidity Biosciences for approximately $12 billion, or $72 per share representing a 46% premium, to bolster its neuroscience pipeline with Avidity's late-stage RNA therapeutics and proprietary Antibody Oligonucleotide Conjugates (AOCs) platform. This strategic acquisition is expected to raise Novartis' 2024-2029 sales compound annual growth rate from 5% to 6%, aligning with its xRNA strategy. Prior to the anticipated first-half 2026 closing, Avidity will spin out its early-stage cardiology programs, while market reaction saw Avidity shares surge 43.4% and Novartis shares decline 1.5%.

Analysis

Novartis AG announced its acquisition of Avidity Biosciences for approximately $12 billion, or $72 per share, representing a substantial 46% premium to Avidity's prior closing price. This strategic move aims to bolster Novartis's neuroscience pipeline with Avidity's late-stage RNA therapeutics and its proprietary Antibody Oligonucleotide Conjugates (AOCs) platform, aligning with Novartis's xRNA strategy. The deal, unanimously approved by both boards, underscores Novartis's commitment to innovative treatments for neuromuscular diseases.

Financially, Novartis anticipates this acquisition will raise its projected 2024-2029 sales compound annual growth rate (CAGR) from 5% to 6%. Prior to the expected first-half 2026 closing, Avidity will spin out its early-stage precision cardiology programs into a new entity, "SpinCo," which will be distributed to existing Avidity shareholders. The transaction remains subject to customary regulatory and shareholder approvals.

Market reaction saw Avidity shares surge 43.4% to approximately $70, reflecting the significant premium offered and a highly positive per-ticker sentiment of 0.9. Conversely, Novartis shares experienced a modest 1.5% decline to around $128, indicating a more neutral initial market assessment (per-ticker sentiment of 0.5) despite the overall "strongly positive" general sentiment for the deal.

Key Decisions for Investors

• Investors holding Avidity Biosciences (RNA) should evaluate the $72 per share cash offer against the potential value of the 'SpinCo' distribution, considering the immediate premium realized versus the long-term prospects of the spun-out cardiology assets.
• Novartis (NVS) shareholders should closely monitor the integration of Avidity's assets and the execution of the xRNA strategy, assessing whether the projected 1% increase in CAGR materializes and justifies the $12 billion acquisition cost.
• Broader institutional investors should observe the regulatory approval process and the clinical progress of Avidity's AOC platform under Novartis, as this acquisition could signal increased M&A activity and validation for RNA therapeutics in specialized disease areas.